Takeda Pharmaceutical Co (TAK) ADR Each Repr 0.5 Share Sponsored

Sell:$15.18Buy:$15.19$0.23 (1.54%)

Prices delayed by at least 15 minutes
Sell:$15.18
Buy:$15.19
Change:$0.23 (1.54%)
Prices delayed by at least 15 minutes
Sell:$15.18
Buy:$15.19
Change:$0.23 (1.54%)
Prices delayed by at least 15 minutes

Company Information

About this company

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

Key people

Christophe Weber
President, Chief Executive Officer, Representative Director
Milano Furuta
Chief Financial Officer, Director
Andrew S. Plump
President of Research & Development, Director
Masami Iijima
Chairman of Board of Directors, Independent Director
Jean-Luc Butel
Independent Director
Ian T. Clark
Independent Director
Yoshiaki Fujimori
Independent Director
Steven H. Gillis
Independent Director
Click to see more

Key facts

  • EPIC
    4502
  • Location
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8740602052
  • Market cap
    $47.41bn
  • Employees
    49,281
  • Shares in issue
    1.59bn
  • Exchange
    Tokyo Stock Exchange
  • Index
    Nikkei 225 Index, TOPIX Stock Price Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.